Skip to content

Released Nov 2, 2023, before the open

10-Q filed Nov 2, 2023, 33 days after period end · 0001628280-23-036187

Q3 2023 · 10-Q
Revenue$17.48M+163.5% vs Q3 2022+212.2% vs Q2 2023
Net Income-$14.35MN/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.34N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$17,081,000N/M
Operating Cash Flowderived-$27,210,000N/M
Free Cash Flowderived-$27,292,000N/M
Margins · derived
Operating margin-97.7%+328.2 pt vs Q3 2022
Net margin-82.1%+306.4 pt vs Q3 2022

What the release said

The release

Same quarter

MetricQ3 2023Q3 2022Q3 2021Q3 2020
Revenue$17.48M$6.63M$41.00K$179.00K
Net Income-$14.35M-$25.77M-$26.08M-$18.37M
EPS Diluted-$0.34-$0.62-$0.71-$3.12

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR